Literature DB >> 31971230

MicroRNAs as sentinels and protagonists of carotid artery thromboembolism.

Sneha Raju1,2,3,4, Jason E Fish1,3,4,5, Kathryn L Howe1,2,3,4.   

Abstract

Stroke is the leading cause of serious disability in the world and a large number of ischemic strokes are due to thromboembolism from unstable carotid artery atherosclerotic plaque. As it is difficult to predict plaque rupture and surgical treatment of asymptomatic disease carries a risk of stroke, carotid disease continues to present major challenges with regard to clinical decision-making and revascularization. There is therefore an imminent need to better understand the molecular mechanisms governing plaque instability and rupture, as this would allow for the development of biomarkers to identify at-risk asymptomatic carotid plaque prior to disease progression and stroke. Further, it would aid in creation of therapeutics to stabilize carotid plaque. MicroRNAs (miRNAs) have been implicated as key protagonists in various stages of atherosclerotic plaque initiation, development and rupture. Notably, they appear to play a crucial role in carotid artery thromboembolism. As the molecular pathways governing the role of miRNAs are being uncovered, we are learning that their involvement is complex, tissue- and stage-specific, and highly selective. Notably, miRNAs can be packaged and secreted in extracellular vesicles (EVs), where they participate in cell-cell communication. The measurement of EV-encapsulated miRNAs in the circulation may inform disease mechanisms occurring in the plaque itself, and therefore may serve as sentinels of unstable plaque as well as therapeutic targets.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  atherosclerosis; carotid; exosomes; extracellular vesicles; microRNA; stroke

Year:  2020        PMID: 31971230     DOI: 10.1042/CS20190651

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  7 in total

Review 1.  Diagnostic and Therapeutic Properties of Exosomes in Cardiac Fibrosis.

Authors:  Jiwen Fan; Meng Ren; Yuquan He
Journal:  Front Cell Dev Biol       Date:  2022-07-04

2.  microRNA-155 Is Decreased During Atherosclerosis Regression and Is Increased in Urinary Extracellular Vesicles During Atherosclerosis Progression.

Authors:  Stephen Fitzsimons; Silvia Oggero; Robyn Bruen; Cathal McCarthy; Moritz J Strowitzki; Niall G Mahon; Nicola Ryan; Eoin P Brennan; Mary Barry; Mauro Perretti; Orina Belton
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

Review 3.  Exosomes in atherosclerosis: performers, bystanders, biomarkers, and therapeutic targets.

Authors:  Chen Wang; Zhelong Li; Yunnan Liu; Lijun Yuan
Journal:  Theranostics       Date:  2021-02-15       Impact factor: 11.556

4.  Circulating Exosomal miRNAs as Novel Biomarkers Perform Superior Diagnostic Efficiency Compared With Plasma miRNAs for Large-Artery Atherosclerosis Stroke.

Authors:  Mengying Niu; Hong Li; Xu Li; Xiaoqian Yan; Aijun Ma; Xudong Pan; Xiaoyan Zhu
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

5.  Circulating microRNAs in Symptomatic and Asymptomatic Carotid Stenosis.

Authors:  Gerrit M Grosse; Anselm A Derda; Ricarda D Stauss; Lavinia Neubert; Danny D Jonigk; Mark P Kühnel; Maria M Gabriel; Ramona Schuppner; Mathias Wilhelmi; Christian Bär; Johann Bauersachs; Claudia Schrimpf; Thomas Thum; Karin Weissenborn
Journal:  Front Neurol       Date:  2021-11-24       Impact factor: 4.003

Review 6.  The Endothelium as a Hub for Cellular Communication in Atherogenesis: Is There Directionality to the Message?

Authors:  Kathryn L Howe; Myron Cybulsky; Jason E Fish
Journal:  Front Cardiovasc Med       Date:  2022-04-15

Review 7.  Search for Reliable Circulating Biomarkers to Predict Carotid Plaque Vulnerability.

Authors:  Núria Puig; Elena Jiménez-Xarrié; Pol Camps-Renom; Sonia Benitez
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.